Berman Capital Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Berman Capital Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$56K	Buy	614 +46	+8%	+$3.54K	0.01%	637
2021 Q2	$44K	Buy	568 +371	+188%	+$28.1K	0.01%	633
2021 Q1	$14K	Buy	197 +141	+252%	+$13K	﹤0.01%	927
2020 Q4	$9K	Buy	56 +11	+24%	+$1.63K	﹤0.01%	965
2020 Q3	$6K	Sell	45 -15	-25%	-$2.28K	﹤0.01%	989
2020 Q2	$9K	Buy	60 +45	+300%	+$6.12K	﹤0.01%	810
2020 Q1	$1K	Sell	15 -13	-46%	-$1.49K	﹤0.01%	1365
2019 Q4	$3K	Buy	28 +15	+115%	+$1.51K	﹤0.01%	1132
2019 Q3	$0	Sell	13 -82	-86%	-$9.68K	﹤0.01%	1567
2019 Q2	$14K	Buy	95 +64	+206%	+$7.78K	﹤0.01%	625
2019 Q1	$3K	Buy	+31	New	+$3.98K	﹤0.01%	1025

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Berman Capital Advisors's SRPT Position: Q3 2021 in Review

Berman Capital Advisors increased its Sarepta Therapeutics (SRPT) stake by 8.1% in Q3 2021, buying an estimated $3.54K and bringing the position to 614 shares worth $56K. The position accounts for 0.01% of the portfolio, ranked #637.

Berman Capital Advisors first reported a position in SRPT in Q1 2019 and has held it in 11 quarters since. 307 funds tracked by Wall St. Rank hold SRPT as of Q3 2021.

Berman Capital Advisors held 614 shares of Sarepta Therapeutics worth $56K as of Q3 2021.
Berman Capital Advisors bought 46 Sarepta Therapeutics shares in Q3 2021, an estimated $3.54K.
Sarepta Therapeutics made up 0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #637 holding.
Berman Capital Advisors first reported a position in Sarepta Therapeutics in Q1 2019 and has held it in 11 quarters since.
307 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.